Continuing Education and Professional Development

The University of Tennessee Graduate School of Medicine Department of Anesthesiology presents:

The recordings from the 2024 Targeted Pain Treatment® Conference which was held on March 22, 2024, at the Hilton Knoxville Airport. This year's conference theme will focus on providing hope for patients with pain.

The Virtual Event Portal platform performs best with the Google Chrome browser on a computer or tablet. If you do not already have Chrome on your computer or tablet (tablets/iPads must be running the latest operating system), you may download it in advance of the meeting. As a last resort, you can do this on your smartphone, however, we do not recommend it, especially if you will need to receive calls. This platform is not designed to be run on a mobile phone.

Course Overview

Health providers are aware of the challenges with the opioid crisis across East Tennessee, as are our patients. As opioids are no longer recommended as first-line therapy for the management of chronic pain, clinicians are at a loss for what options are out there for those patients whose quality of life is limited by their pain. Our goal is to provide clinicians and patients with the hope that there is a way to effectively treat their pain and improve their function without relying solely on opioids.

Course Objectives

After this program, the participants should be able to:

• Discuss the scientific basis of hope and how scientific theory relates to targeted pain treatment
• Identify ways to apply the state and national guidelines that govern opioid prescribing and chronic pain treatment
• Discuss specific treatment options to address challenging pain presentations

Targeted Pain Treatment the process of accurately diagnosing  the cause of pain, and then targeting the treatment to the cause, is an alternate, effective, and comprehensive approach to addressing the cause of pain and improving function and quality of life for patients.  

This conference is officially endorsed by the Tennessee Pain Society.

Requirements for continuing medical education credit regarding controlled substance prescribing

Targeted Pain Treatment® the process of accurately diagnosing the cause of pain, and then targeting the treatment to the cause, is an alternate, effective, and comprehensive approach to addressing the cause of pain and improving function and quality of life for patients. Targeted Pain Treatment® is a federally registered trademark owned by Dr. Stephanie Vanterpool. Dr. Vanterpool developed and is responsible for the content contained in the TPT Toolkit.

Accreditation

The University of Tennessee College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Education Credits

The University of Tennessee College of Medicine designates this enduring activity for a maximum of 6.75 AMA PRA Category 1 Credits Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants, Nurse Practitioners and Nurses may use these credit hours toward certification renewal.  This credit is acceptable by the American Academy of Physician Assistants (AAPA), American Nurses Credentialing Association (ANCC) and the American Academy of Nurse Practitioners (AANP).

Disclosures

There is no minimum threshold for financial disclosures; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies within the past 24 months. Individuals must disclose regardless of their view of the relevance of the relationship to the education. Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

The UT Graduate School of Medicine Office of Continuing Education and Professional Development along with the Co-Course Directors have taken appropriate steps to mitigate relationships prior to the individuals assuming their roles.  CME Planning Staff have no actual or potential conflicts of interest concerning the presentations.

The following presenters have no financial relationships with ineligible companies to disclose: 

Hannah Denham, PharmD (Co-Course Director)
Shrivani Durbhakula, MD
Amber Hampton, MD
Stephen Loyd, MD
George Mears, FNP
Jennifer Mitchell, PA-C
Veera Motashaw, DO
Alopi Patel, MD
Che Solla, MD
Matthew Vance, MD
Audrey Wohl, FNP-BC 

Before the conference, the following presenters make these disclosures, which have been reviewed by a non-conflicted co-course director, along with the presentation slides. All relevant financial relationships have been mitigated:

Tammy Dann, DO
Relationships: Speaker's Bureau for Medtronic & Consultant for Medtronic, AIS, TerSera

Mark Jones, MD
Relationships: Consultant for Nevro

Stephanie Vanterpool, MD (Co-Course Director)
Relationship: Advisor for SureMed Compliance